NanoLogix Study Confirms Early Success Of Hydrogen Bioreactor

    SHARON, Pa., May 9 /PRNewswire-FirstCall/ -- NanoLogix, Inc., (Pink
 Sheets: IFEC), a Nanobiotechnology company engaged in the research,
 development and commercialization of technologies for the production of
 bacteria and disease testing kits, alternative sources of fuel, cancer therapy
 and remediation of toxic materials, announces that preliminary data and
 results of a study which confirms laboratory proof-of-concept measurements
 have shown it possible to generate hydrogen in high yields via the use and
 adaptation of its intellectual property.  In this study, the bioreactor
 produced biogas consisting of 50% hydrogen by volume, without any trace of
 methane.
     Recently, NanoLogix, Inc. (formerly Infectech, Inc.) signed a feasibility
 study with the Department of Environmental Science and Engineering of Gannon
 University in Erie, PA to develop a bioreactor which utilizes NanoLogix's
 patented bacterial culturing methods in order to produce hydrogen
 inexpensively.  Hydrogen reacts with oxygen to yield significant amounts of
 energy, and has the added benefit of not producing carbon dioxide as a
 by-product (the reaction between hydrogen and oxygen simply generates water
 vapor).  NanoLogix believes they have discovered the most likely method for
 low cost production of massive quantities of hydrogen as an alternate energy
 source.  NanoLogix has ascertained through its patent counsel that additional
 patents will be pending beyond those already filed.
 
     About NanoLogix
     NanoLogix, Inc., formerly known as Infectech, Inc.
 (http://www.infectech.com), is a technology application innovator of biogas
 products and services designed to assist in worldwide energy independence and
 reduce pollution from renewable, environmentally-friendly energy sources.
 NanoLogix is also engaged in the research and development of diagnostic test
 kits designed to be used for the rapid identification of infectious human
 diseases. The Company's patents span the identification and antibiotic
 sensitivity testing of 34 disease-producing bacteria, including M.
 tuberculosis (TB), Mycobacterium avium-intracellulare (MAI), pseudomonas, and
 nocardia. These bacteria are cited as prominent causes of morbidity and
 mortality in patients with cancer, cystic fibrosis, and AIDS. Additionally,
 NanoLogix owns a patent for the nontoxic induction of apoptosis in cancer
 cells utilizing hydrophobic hydrocarbons. Apoptosis is a method for inducing a
 genetically based induction of "cell suicide" in cells. The Company's 31
 patents can be viewed by visiting
 http://www.infectech.com/intellectual_property.php .
 
     About Nanotechnology
     The convergence of science, medicine and technology is on the cusp of
 yielding extraordinary breakthroughs.  Today, patents that were once designed
 to identify bacteria have widespread applications across multiple markets.  At
 the heart of this convergence is nature.  All things begin and end with the
 building blocks of life.  NanoLogix's portfolio of 31 patents have yielded a
 method vital to the development of biophasic system devices intended for
 medical purposes to cultivate and identify certain pathogenic microorganisms.
 The devices contain one or more components that suppress the growth of certain
 microorganisms while either promoting or not affecting the growth of other
 microorganisms.  The FDA registered devices aid in the diagnosis of disease
 caused by the pathogenic microorganisms. products, a method for low cost
 hydrogen production, a genomic cancer therapy and methods for cleaning up
 toxic environments using bioremediation.
     NanoLogix's patents have nanotechnology applications in medical
 drugs/devices, bio-defense sensors, hydrogen production, cancer treatment and
 bioremediation.  Nanotechnology applications include Biochips embedded in
 small transportable devices for rapid bacteria identification of disease
 causing pathogens, and Bio Micro Electro Mechanical Systems ("BioMEMS") for
 rapid environmental microbial monitoring with bio-defense implications. Its
 hydrogen bioreactor research is designed to assist in worldwide energy
 independence and reduce pollution using renewable, environmentally-friendly
 energy sources.  NanoLogix's FDA registered diagnostic test kits are designed
 to be used for the rapid identification of infectious human diseases and
 identify 34 disease-producing bacteria, including Tuberculosis (TB),
 Mycobacterium avium-intracellulare (MAI), Pseudomonas, and Nocardia. These
 bacteria are cited as prominent causes of morbidity and mortality in patients
 with cancer, cystic fibrosis, and AIDS, as well as in patients undergoing
 surgery. Additionally, NanoLogix owns a patent for the nontoxic induction of
 apoptosis in cancer cells utilizing hydrophobic hydrocarbons. Apoptosis is a
 method for inducing a genetically based induction of "cell suicide" in cells.
 It therefore serves as the foundation for cancer therapy. NanoLogix's other
 patents include technology designed for use in the bioremediation of
 contaminated soil and water.
 
     This press release contains statements, which may constitute "forward-
 looking statements" within the meaning of the Securities Act of 1933 and the
 Securities Exchange Act of 1934, as amended by the Private Securities
 Litigation Reform Act of 1995. Those statements include statements regarding
 the intent, belief or current expectations of NanoLogix, Inc., and members of
 its management as well as the assumptions on which such statements are based.
 Prospective investors are cautioned that any such forward-looking statements
 are not guarantees of future performance and involve risks and uncertainties,
 and that actual results may differ materially from those contemplated by such
 forward-looking statements. Important factors currently known to management
 that could cause actual results to differ materially from those in forward-
 statements include fluctuation of operating results, the ability to compete
 successfully and the ability to complete before-mentioned transactions. The
 company undertakes no obligation to update or revise forward-looking
 statements to reflect changed assumptions, the occurrence of unanticipated
 events or changes to future operating results.
 
 

SOURCE NanoLogix, Inc.

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.